Group One Trading’s Dianthus Therapeutics DNTH Stock Holding History

Group One Trading’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$536K	Sell	5,500 -900	-14%	-$78.6K	﹤0.01%	3432
2026 Q1	$537K	Buy	+6,400	New	+$371K	﹤0.01%	3282
2025 Q4	–	Sell	-13,200	Closed	-$519K	–	8338
2025 Q3	$519K	Buy	+13,200	New	+$337K	﹤0.01%	3664
2021 Q1	–	Sell	-19	Closed	-$2K	–	7659
2020 Q4	$2K	Sell	19 -6	-24%	-$680	﹤0.01%	6238
2020 Q3	$3K	Buy	25 +19	+317%	+$2.25K	﹤0.01%	5739
2020 Q2	$1K	Hold	6	–	–	﹤0.01%	5634
2020 Q1	$1K	Hold	6	–	–	﹤0.01%	5067
2019 Q4	$2K	Buy	+6	New	+$1.12K	﹤0.01%	4889

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Group One Trading's DNTH Position: Q2 2026 in Review

Group One Trading reduced its Dianthus Therapeutics (DNTH) stake by 97% in Q2 2026, selling an estimated $294K and leaving 89 shares worth $8.68K. The position accounts for ﹤0.01% of the portfolio, ranked #6480.

Group One Trading first reported a position in DNTH in Q4 2019 and has held it in 7 quarters since. The position peaked at $290K in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Group One Trading held 89 shares of Dianthus Therapeutics worth $8.68K as of Q2 2026.
Group One Trading sold 3,364 Dianthus Therapeutics shares in Q2 2026, an estimated $294K.
Dianthus Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6480 holding.
Group One Trading first reported a position in Dianthus Therapeutics in Q4 2019 and has held it in 7 quarters since.
Group One Trading's Dianthus Therapeutics position peaked at $290K in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.